Fracture Incidence Reduction and Safety of TSE-424 (Bazedoxifene Acetate) Compared to Placebo and Raloxifene in Osteoporotic Postmenopausal Women.
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Bazedoxifene (Primary) ; Raloxifene
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 12 Jun 2011 Results presented at the 13th World Congress on Menopause.
- 22 Feb 2011 Additional locations added as reported by ClinicalTrials.gov.
- 22 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.